Core Viewpoint - The company, Pulaike (普莱柯), plans to acquire a 4.04% stake in Zhongpu Biopharmaceutical Co., Ltd. (中普生物) from CITIC Agricultural Technology Co., Ltd. (中信农业), which will enhance its control over the veterinary vaccine market, particularly in foot-and-mouth disease vaccines, aligning with its long-term development strategy [1][2]. Group 1 - The acquisition will allow Pulaike to gain control over Zhongpu Biopharmaceutical, improving its product matrix and business synergy in the livestock vaccine sector [1][2]. - Zhongpu Biopharmaceutical was established in June 2018 by Pulaike, China Animal Husbandry Industry Co., Ltd. (中牧股份), and CITIC Agricultural, with current ownership stakes of 46.97%, 48.99%, and 4.04% respectively [1]. - The stake being acquired is valued at 17.5143 million yuan (approximately 2.5 million USD) [1]. Group 2 - Zhongpu Biopharmaceutical reported net losses of 26.2074 million yuan (approximately 3.7 million USD) for 2024 and 18.237 million yuan (approximately 2.6 million USD) for the first half of the year [3]. - Pulaike aims to improve Zhongpu's operational efficiency and sustainability through this acquisition, which is in line with its strategic planning and shareholder interests [3]. - The acquisition may require Pulaike to invest additional resources to optimize Zhongpu's business model, which could have a short-term impact on its profits [3].

Core Viewpoint - The announcement by Pulaike (603566) regarding the potential acquisition of a 4.04% stake in Zhongpu Biological by the company, which would lead to control over Zhongpu Biological if the stake is acquired [1] Group 1: Company Information - Zhongpu Biological was established in June 2018 with investments from the company, Zhongmu Co., Ltd. (600195), and CITIC Agriculture, primarily focusing on foot-and-mouth disease vaccine business [1] - The company currently holds a 46.97% stake in Zhongpu Biological [1] Group 2: Share Transfer Details - CITIC Agriculture is offering its 4.04% stake in Zhongpu Biological for transfer at a base price of 17.5143 million yuan [1] - The company has a priority purchase right for this stake, which it may exercise depending on whether a third party acquires the stake [1] - If no third party acquires the stake, the company will proceed to acquire it, thereby gaining control over Zhongpu Biological [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-049 普莱柯生物工程股份有限公司 关于拟认购中信农业所持中普生物股权暨购买资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 中普生物由普莱柯、中牧实业股份有限公司（以下简称"中牧股份"）和中 信农业于 2018 年 6 月共同出资成立，经营范围主要为口蹄疫疫苗业务；截至目 前，普莱柯持股比例为 46.97%，中牧股份持股比例为 48.99%，中信农业持股比 例为 4.04%。 近日，中信农业将其持有的中普生物 4.04%股权在上海联合产权交易所挂牌 转让，转让标的对应评估值和转让底价为 1,751.43 万元。公司为改善中普生物经 营状况，根据长远发展需要，拟受让该部分股权。根据中普生物股东协议，经中 牧股份同意后，公司拥有对该部分股权的优先购买权。近日，公司收到中牧股份 函件，同意解除对公司购买该部分股权的限制。如有第三方摘牌，公司将视情况 决定是否行使优先购买权；如无第三方摘牌，公司将受让该部分股权，并获得中 交易内容概 ...

格隆汇12月2日丨普莱柯(603566.SH)公布，近日，中信农业将其持有的中普生物4.04%股权在上海联合 产权交易所挂牌转让，转让标的对应评估值和转让底价为1,751.43万元。公司为改善中普生物经营状 况，根据长远发展需要，拟受让该部分股权。根据中普生物股东协议，经中牧股份同意后，公司拥有对 该部分股权的优先购买权。近日，公司收到中牧股份函件，同意解除对公司购买该部分股权的限制。如 有第三方摘牌，公司将视情况决定是否行使优先购买权；如无第三方摘牌，公司将受让该部分股权，并 获得中普生物的控制权。 ...

智通财经APP讯，普莱柯(603566.SH)发布公告，公司拟认购中信农业科技股份有限公司(简称"中信农 业")持有的中普生物制药有限公司(简称"中普生物")股权。若本次交易能够完成，公司将获得中普生物 的控制权。 ...

普莱柯（603566）(603566.SH)发布公告，公司拟认购中信农业科技股份有限公司(简称"中信农业")持有 的中普生物制药有限公司(简称"中普生物")股权。若本次交易能够完成，公司将获得中普生物的控制 权。 ...

Core Viewpoint - The company, Pulaike, plans to acquire a 4.04% stake in Zhongpu Bio held by CITIC Agriculture, with the transfer valuation and minimum transfer price set at 17.5143 million yuan [1] Group 1: Transaction Details - CITIC Agriculture is transferring its 4.04% stake in Zhongpu Bio, which primarily focuses on foot-and-mouth disease vaccine business [1] - Pulaike, Zhongmu Co., and CITIC Agriculture hold 46.97%, 48.99%, and 4.04% stakes in Zhongpu Bio, respectively [1] - Pulaike has the right of first refusal for this stake acquisition [1] Group 2: Corporate Governance - The board of directors of Pulaike has approved the transaction on December 2, 2025, and it does not require shareholder approval [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] Group 3: Control Implications - If the transaction is completed, Pulaike will gain control over Zhongpu Bio [1]

Core Viewpoint - The animal health sector experienced a decline of 0.48% on December 1, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index rising by 0.65% and the Shenzhen Component Index increasing by 1.25% [1][2]. Market Performance - The closing price of *ST Lvkang was 39.35, reflecting a decrease of 3.41% with a trading volume of 30,400 shares and a transaction value of 122 million yuan [2]. - Other notable stocks in the animal health sector included: - Dayu Biological: Closing price 8.26, up 2.10% [1] - Haili Biological: Closing price 6.86, up 1.03% [1] - Qihua Biological: Closing price 15.85, up 0.51% [1] - Repu Biological: Closing price 19.83, down 0.10% [1][2]. Capital Flow - The animal health sector saw a net outflow of 29.57 million yuan from institutional investors, while retail investors contributed a net inflow of 3.27 million yuan [2][3]. - Specific stock capital flows included: - Jinhai Biological: Net inflow from institutional investors of 3.13 million yuan [3]. - Haili Biological: Net inflow from institutional investors of 2.06 million yuan [3]. - Repu Biological: Net inflow from retail investors of 2.81 million yuan [3].

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第二次临时股东大会的 法律意见 德恒 01G20250867-01 号 致： 普莱柯生物工程股份有限公司 北京德恒律师事务所受普莱柯生物工程股份有限公司（以下简称"普莱柯" 或"公司"）委托，指派黄丰、赖元超律师（以下简称"本所律师"）出席普莱 柯 2025 年第二次临时股东大会（以下简称"本次股东大会"），对本次股东大 会的合法性进行见证并出具法律意见。 本所及本所律师根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》的规定及本法律意见出具日以前已经发生或者存在的事实，严格履 行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分 ...